“Magic mushrooms” may soon become legal in Oregon, where even powerful politicians seem high — on the idea, according to a report.
The state’s attorney general green-lit language allowing the bill to hit the ballots in 2020, assuming advocates get enough signatures, according to Oregonlive.com
If it passes, the initiative would decriminalize hallucinogenic mushrooms and allow them to be manufactured with a license. Oregon would become the first US state to legalize the drug.
The bill will need 140,000 signatures in order to appear on the ballots in the 2020 general election, the paper reported.
Nationwide, possession of psychedelic mushrooms — and their active compound, psilocybin — is a felony.
But advocates say the trippy treat can help boost spirituality, fight depression and even help terminally ill patients cope with death.
Rolling Stone reports:
“The intent of the 2020 Psilocybin Service Initiative of Oregon is to advance a breakthrough therapeutic model currently being perfected in research settings at top universities around the world, chief petitioners behind the initiative Tom and Sheri Eckert wrote on their website.
“We envision a community-based framework, where licensed providers, along with licensed producers of psilocybin mushrooms, blaze trails in Oregon in accordance with evolving practice standards.”
Research into psilocybin is part of a larger trend of promising results in psychedelics-assisted psychotherapy, with once-feared drugs like LSD (acid) and MDMA (ecstasy) getting new life as potential medicine, with growing support for medical and recreational paving the way.
LSD has shown promise as a way to help terminally ill patients prepare for death with less anxiety and fear, and MDMA-assisted psychotherapy for PTSD is currently in clinical trials and could be available by prescription as soon as 2021.
Much of the medicinal psychedelics research currently underway is being led, or at least supported, by the Multidisciplinary Association of Psychedelic Studies (MAPS).
“We believe that drug policy should be grounded in science and compassion, so MAPS’ current policy priorities are eliminating barriers to psychedelic and marijuana research, and promoting harm reduction,” says Brad Burge, Director of Strategic Communications for MAPS, who also says the organization supports ballot initiatives, but is currently more focused on their work with the FDA.
“MAPS’ mission is to develop medical, legal and cultural contexts for the careful and beneficial use of psychedelics. In these contexts, no one would be criminalized for the possession or use of psychedelics, or any drugs. People would have access to legal, regulated markets, both medical and otherwise, to safely benefit from intentional psychedelic use.”
It will be interesting to see how this all turns out.